Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.38, $0.32 better than the analyst estimate of $4.06. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.43 billion.

GUIDANCE:

Amgen sees 2021 EPS of $16.00-$17.00, versus the consensus of $16.34. Amgen sees 2021 revenue of $25.8-26.6 billion, versus the consensus of $26.04 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Femcare acquires UK harm reduction firm Orion for £3.6M
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance